INTRODUCTION
Until recently, the benefits of solid-organ transplantation for the treatment of end-stage liver and kidney disease were denied in the HIV-infected patients because of fears that the surgery itself or the subsequent immunosuppressive requirements would exacerbate progression of HIV and associated sequelae. The development of combination antiretroviral therapy (cART) has dramatically improved the long-term control of HIV, which has been accompanied by greater numbers of patients with long-term exposure to hepatitis B and C, and in turn greater numbers of patients with cirrhosis, end-stage liver disease and hepatocellular cancer. Several factors have led to increased numbers of HIV-infected patients with end-stage kidney disease, including long-term exposure to HIV medications, coinfection with HCV and an overall aging population. The disease burden of end-stage organ failure combined with growing confidence in the efficacy of cART has led many centers to begin offering solid-organ transplantation to HIV-infected patients under strict selection criteria with the expectation of sustained posttransplant control of HIV, and the number of published reports of transplantation in this patient group continues to steadily increase.
The selection criteria for solid-organ transplantation in HIV-infected patients include a minimum evidence of sustained control of HIV, a reasonably well preserved CD4 count and the absence of significant active opportunistic infection or neoplasia. Most of the remaining selection criteria for liver or kidney transplantation in HIV-infected patients are similar to those in non-HIV-infected patients, although debate over the value of liver transplantation in the setting of hepatitis C virus (HCV) coinfection continues and is covered below. Most importantly, because of the complex interactions between antiretroviral therapy and immunosuppressive medications and because of the potential confounding factors that HIV infection introduces, solid-organ transplantation should only be undertaken at centers with extensive HIV experience and with well functioning multidisciplinary care teams. The exclusion criteria for liver and/or kidney transplantation in HIV-positive patients are as follows:
(1) medical or psychosocial contraindication to transplantation; (2) CD4 count less than 200 (or <100 for liver); (3) detectable HIV viral load (unless cART therapy held because of hepatotoxicity); (4) multidrug-resistant HIV or unstable cART regimen; (5) recent malignancy other than hepatocellular carcinoma (HCC); (6) active opportunistic infection (pulmonary coccidiomycosis patients must be disease free for 5 years); (7) substantial wasting; (8) history of progressive multifocal leukoencephalopathy, chronic cryptosporidosis, AIDSassociated lymphoma or multidrug-resistant fungal infection.
The largest series to date of solid-organ transplantation in the HIV-infected patients is an ongoing NIH-funded, U.S. multicenter prospective trial (HIV-TR), in which 150 HIV-positive patients underwent kidney transplantation and 125 patients underwent liver transplantation between 2003 and 2010 [1] . In this study, patients undergoing kidney transplantation had a 1-year and 3-year patient survival of 94 and 88%, and 1-year and 3-year graft survival of 90 and 74%, respectively [2 && ]. These graft survival rates were felt to be acceptable but slightly below that seen in historical non-HIVinfected patients, likely because of the higher rates of acute rejection. Sustained control of HIV viral load after transplant was excellent, with only five cases of HIV-related neoplasia or HIV progression noted.
In patients undergoing liver transplantation in the HIV-TR study, the outcomes of liver transplantation for hepatitis B were excellent, with 3-year patient survival of 85% [3] . However, in patients with HCV and HIV coinfection, the patient and graft survival rates were lower, with 3-year patient and graft survival of 60 and 53%, respectively. This survival rate was significantly lower than that seen in a matched control group of non-HIV HCV patients [4 & ]. Several factors were identified which increased the risk of graft loss in HIV and HCV infected patients, including older donor age, combined liver and kidney transplant, use of an HCV positive donor and a body mass index of under 21 in the recipient. In HIV and HCV patients without these risk factors, the 3-year patient survival was similar to that of non-HIV-infected patients undergoing liver transplantation for HCV, leading to the conclusion that liver transplantation in the HIV and HCV patient can be safely undertaken with careful donor and recipient selection. In this more recent report from the HIV-TR study, there were again no deaths attributable to HIV progression or opportunistic infection.
In a recent review and meta-analysis of liver transplant outcomes in HIV-infected patients, Cooper et al. [5] analyzed individual data from 15 cohort studies and 49 case series. This study identified 686 patients undergoing liver transplantation and found overall survival at 1, 3 and 5 years of 85, 66 and 64%, respectively. Further analysis of a subset of these patients found markedly better survival in patient with hepatitis B and HIV coinfection (compared to those without hepatitis B) and worse survival in those with detectable HIV viral load at the time of transplant. The presence of hepatitis C predicted worse overall survival in unadjusted analysis, but was not associated with worse survival when adjusted for other confounding variables.
Specific analysis of the immune system after liver transplantation in the HIV patients has been undertaken by several investigators. Samri et al. [6] KEY POINTS Kidney and liver transplantation are successful in carefully selected HIV-positive patients, with graft and patient survival approaching those of non-HIV-infected patients.
HIV-positive patients undergoing liver transplantation for hepatocellular carcinoma have low recurrence rates and generally fare as well as non-HIV-infected patients.
De-novo malignancies including skin cancer and Kaposi's sarcoma can occur after solid-organ transplantation in these patients, but do not appear to occur with increased incidence.
Preliminary results suggest that human papilloma virusmediated anal lesions may have an accelerated progression after transplantation. This requires more study.
as part of the THEVIC trial in France reported on the immune responsiveness in HIV and HCV patients after liver transplantation and found that anti-HCV responsiveness as well as immune competence against HIV and opportunistic pathogens such as candida was preserved in patients who were receiving a tacrolimus-based and steroid-based immunosuppressive regimen. Patients with aggressive HCV recurrence after liver transplantation lacked the immune responsiveness to HCV, suggesting a dire need for better HCV treatments after liver transplantation in the subset with deficient HCV immunocompetence.
HEPATOCELLULAR CANCER AND HIV
HCC is the fourth leading cause of cancer death worldwide, with over 1 million new cases diagnosed worldwide yearly. The primary risk factor for HCC is the presence of cirrhosis, although HCC commonly develops in the patient with hepatitis B even without underlying cirrhosis. The same factors that have led to increasing numbers of HIV-positive patients presenting with end-stage liver disease are leading to increased occurrence of HCC, as coinfection with HCV and hepatitis B virus puts these patients at risk for cirrhosis and in turn HCC.
There is a growing body of evidence that the pattern of occurrence of HCC is different in the HIVinfected patients than in the non-HIV patients. A recent French observational study by Bourcier et al. [7 ] analyzed two cohorts of liver cancer, those with HIV-HCV coinfection and those with HCV alone. In this study, HCC occurred at a younger age in those with HIV-HCV coinfection (48 vs. 60 years old) and presented at a more advanced stage and was associated with worse outcome in the HIV-HCV group. An Italian observational study which compared HIV-infected to noninfected patients also reported the mean age at the time of occurrence is younger in the HIV patients. This study did not find tumors to be more advanced in HIV patients at presentation, but found significantly shorter survival times and fewer attempts at cancer retreatment in HIV patients [8] .
These reports and several similar reports have led to assertions that HIV is itself a risk factor for HCC in patients with underlying liver disease, and that it may be more aggressive and more lethal in the HIV-infected patients. In a review of a large cohort of HIV patients followed prospectively in France, Bruyand et al. [9] reported that CD4 counts less than 500 were associated with higher incidence of HCC, but that the overall duration of immunodeficiency was not associated with increased risk.
LIVER TRANSPLANTATION FOR HEPATOCELLULAR CARCINOMA
Liver transplantation is an attractive treatment option for HCC because it simultaneously addresses the hepatic tumor burden as well as the underlying liver disease and liver dysfunction. Risk of recurrent HCC after liver transplantation is largely related to the stage and morphology of the tumor at the time of transplant, as de-novo HCC should no longer form in the absence of the 'fertile soil' of the pretransplant cirrhotic liver. Liver transplantation has been widely accepted as a valuable treatment for HCC in patients with cirrhosis since the landmark study by Mazzaferro et al. [10] which reported survival rates of 75% at 4 years in patients undergoing liver transplantation for HCC that was within the Milan criteria (consisting of single hepatic lesion <5 cm, or two or three lesions <3 cm).
Despite the worldwide acceptance of liver transplantation for HCC that is within the Milan criteria, few reports have been published on liver transplantation in HIV-positive patients with HCC. In a recent study from France, Vibert et al. [11 & ] reported on 16 HIV-positive patients undergoing liver transplantation for HCC and found no significant difference in overall survival or recurrence-free survival compared to 58 non-HIV patients with HCC from the same time period. Most patients were within the Milan criteria. Three-year overall and recurrencefree survival in the HIV-HCC patients in this study were 85 and 74% compared to 93 and 81%, respectively, in a non-HIV patient group. Similar to other studies, the HIV-HCC patients in this transplant population were younger than their non-HIV counterparts (48 vs. 57 years) and had higher alpha-fetoprotein levels. The drop-out rate, or the number of patients who were listed for liver transplantation but ultimately were not able to undergo liver transplantation, was suggested to be higher in the HIV-positive group, with 5 of 21 listed patients dropping out because of tumor progression (n ¼ 4) or HIV progression (n ¼ 1). Five of sixteen patients (31%) experienced HCC recurrence at a median 11 months postliver transplantation which was not significantly greater than in the non-HIV and non-HCC group (P ¼ 0.15). The authors in this report favored cyclosporine immunosuppression and did not routinely alter their immunosuppressive regimen in the HIV and HCC patients.
In a report from the University of Modena, investigators describe performing liver transplantation in 23 patients with HIV coinfection, including 14 patients with HCC. Ten of these fourteen patients were within the Milan criteria and four were outside of the Milan criteria. No cases of recurrence are reported, but 10 patients died overall. Cause of death was primarily because of recurrent hepatitis C or infectious complications for an overall patient and graft survival at 80 months of 50 and 45%, respectively. The authors report favoring an immunosuppressive regimen of the mammalian target of rapamycin (mTOR) inhibitor rapamycin over calcineurin inhibitors in the HIV and HCC liver transplantation patients, presumably because of possible antitumor effects of rapamycin. One patient with postliver transplantation Kaposi's sarcoma had resolution of lesions after conversion to rapamycin [12 & ].
In the HIV-TR study, HCC (majority within Milan criteria) was present in 45 (36%) of the 125 liver patients undergoing liver transplantation. HCC recurrence has been seen in two patients at a median follow-up of 34 months. The majority of patients in this report were maintained on calcineurininhibitor-based immunosuppressive regimens.
These reports demonstrate the utility of liver transplantation as a treatment for HCC in the HIV-infected patients. Careful patient selection is critical, primarily related to the risk factors for recurrent HCV infection noted above. The majority of evidence, however, suggests that in appropriately selected patients the risk of recurrent HCC after liver transplantation in the HIV-positive patient is low. The use of mTOR-based immunosuppressive strategies in the HIV-HCC patient after liver transplantation is compelling but not universally practiced, and at present, there are few data to support the routine use of rapamune or similar agents over the more commonly utilized calcineurin inhibitorbased regimens. In addition, there are no data on the use of the multikinase inhibitor sorafenib in the treatment of HCC in the HIV-positive patients.
NEOPLASIA AFTER TRANSPLANTATION IN THE HIV PATIENTS
Solid-organ transplantation brings with it the need for lifelong immunosuppressive therapy. One of the concerns over transplantation in the HIV-positive patients is that the addition of immunotherapy to the already immunosuppressed patient would lead to increased neoplasia, either in the form of recurrent malignancies (such as in the patient transplanted for HCC) or new malignancies. In the ongoing HIV-TR trial of 275 total transplant patients, 25 patients (9%) developed posttransplant malignancy and 7 patients (3%) died from a cancerrelated cause. In the group undergoing kidney transplantation, 13 out of 150 patients (8.7%) had developed 14 malignancies at a median follow-up of 3.5 years after transplant. This included skin cancer (n ¼ 5), cutaneous Kaposi's sarcoma (n ¼ 3), penile squamous cell cancer (n ¼ 1), head and neck cancer (n ¼ 3) and renal cell cancer (n ¼ 2). There were three cancer-related deaths in kidney transplantation. In 125 patients undergoing liver transplantation in this study, 12 patients developed 14 malignancies at a median follow-up of 2.8 years after transplant. De-novo malignancies in this group included skin cancer (n ¼ 9), Kaposi's sarcoma (n ¼ 1) and lymphoma (n ¼ 1). Three patients had recurrence of preliver transplantation malignancy, including two HCC and one cholangiocarcinoma.
At present, the incidence of malignancy after solid-organ transplantation in the HIV-infected population does not appear to be significantly different than that seen in non-HIV-infected patients. Kaposi's sarcoma, thought to be driven at least in part by HHV8 proliferation related to the immunosuppression that accompanies transplantation, was recently reported to occur at a rate of approximately 2% after liver transplantation [13] , similar to that in the HIV-TR trial. All de-novo Kaposi's sarcoma lesions in the HIV-TR study were cutaneous, and all were treated successfully with the addition of rapamycin to the immunosuppressive regimen. Rapamycin, a TOR-inhibitor used as an alternative immunosuppressive agent, also has well documented therapeutic effects on Kaposi's sarcoma [14] . Similarly, the rates of de-novo head and neck cancers and of recurrent HCC after liver transplantation are relatively low in the HIV-TR study and other similar reports, and are in line with those reported in the non-HIV transplant populations [15] .
Another goal of the HIV-TR multicenter study was to prospectively monitor the progression of human papilloma virus (HPV)-associated neoplasia in the HIV-infected patients undergoing solid-organ transplantation. In 89 patients followed prospectively for anal cytology, there was increased risk of developing high-grade squamous intraepithelial lesions (HSILs) after transplantation. The development of HSIL in these patients was not influenced by the type of organ transplant (kidney vs. liver) or by the use of T-cell-depleting agents. Clearly, this group requires further study to determine the longitudinal impact of transplant-related immunosuppression on HPV-related neoplasia.
CONCLUSION
HIV infection is no longer a contraindication to solid-organ transplantation. Control of HIV infection has been excellent in most studies, but the recurrence rate of HCV after liver transplantation continues to be a difficult problem. Most aspects of the management of malignancy in the HIV-infected transplant patients parallel that of the non-HIVinfected patients. Further investigation into the effects of transplant on risk of neoplasia, particularly
